Table 2 Mean lung severity scores of the investigational veterinary product (IVP)-treated groups (Bravecto® Plus spot-on, minimum recommended dose of 40 mg fluralaner and 2.0 mg moxidectin/kg body weight; G1, G2, G3) and the control group (0.9% saline; G4). Comparison of mean lung severity scores of the IVP-treatment groups versus the control group by two-sided Wilcoxon rank-sum test
Group | Pre-enrolment (SD −7 to −2) | Before inoculation (SD 75 to 78) | Post inoculation (SD 131 to 134) | |||
|---|---|---|---|---|---|---|
Mean | p-Value | Mean | p-Value | Mean | p-value | |
G1 (IVP treatment 12 weeks prior to infection) | 0.29 | 1.0000 | 0.86 | 0.6166 | 1.43 | 0.0006* |
G2 (IVP treatment 8 weeks prior to infection) | 0.14 | 1.0000 | 0.71 | 0.6329 | 0.50 | 0.0022* |
G3 (IVP treatment 4 weeks prior to infection) | 0.43 | 1.0000 | 0.71 | 0.3502 | 1.14 | 0.0006* |
G4 (no IVP treatment, control) | 0.29 | – | 1.00 | – | 3.00 | – |